---
title: "Skyrizi (risankizumab-rzaa), all indications: Drug interactions questions"
description: "Drug interactions questions on Skyrizi (risankizumab-rzaa) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: Does Skyrizi have drug interactions? 1 question quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/skyrizi/drug-interactions"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T01:54:55-05:00"
---

# Skyrizi (risankizumab-rzaa), all indications: Drug interactions questions

Manufacturer: AbbVie Inc.  
Prescribing information: [Skyrizi](https://www.skyrizihcp.com/prescribinginfo)  
Indication pages: [Plaque psoriasis](https://www.evicenter.com/medical-information/skyrizi--plaque-psoriasis)

## Drug interactions

<a id="skyrizi-drug-interactions"></a>

### Does Skyrizi have drug interactions?

> “No clinically significant changes in exposure of caffeine (CYP1A2 substrate), warfarin 
> (CYP2C9 substrate), omeprazole (CYP2C19 substrate), metoprolol (CYP2D6 substrate), or 
> midazolam (CYP3A substrate) were observed when used concomitantly with risankizumab-rzaa 
> in subjects with plaque psoriasis (risankizumab-rzaa 150 mg administered subcutaneously at 
> Weeks 0, 4, 8, and 12) and subjects with Crohn’s disease or ulcerative colitis (risankizumab-rzaa 
> 1,800 mg administered intravenously at Weeks 0, 4, and 8, i.e., 3 times and 1.5 times the 
> recommended dose for Crohn’s disease and ulcerative colitis, respectively).”

Source: [SKYRIZI: Prescribing information, page 20, captured 2026-11-12](https://www.skyrizihcp.com/prescribinginfo#page=20)

> “NO
>
> labeled drug interactions<sup>1†</sup>”

Source: [SKYRIZI: SKYRIZI® (risankizumab-rzaa) Clinical Safety Profile for Ps & PsA, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/pso-psa-safety-profile#:~:text=symptoms%20of%20infection.-,NO,labeled%20drug)

## Related pages
- [Medical information: Skyrizi (risankizumab-rzaa): All indications](https://www.evicenter.com/medical-information/skyrizi)
- [Pharmacology](https://www.evicenter.com/medical-information/skyrizi/pharmacology)
- [Safety](https://www.evicenter.com/medical-information/skyrizi/safety)
- [Specific populations](https://www.evicenter.com/medical-information/skyrizi/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/skyrizi/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/skyrizi/storage-and-supply)
